AstraZeneca Pharma gets ₹148.66 cr NPPA demand in 2026

What the latest NPPA notices say

AstraZeneca Pharma India Ltd has disclosed that it received demand notices from the National Pharmaceutical Pricing Authority (NPPA) alleging overcharging under the Drugs (Prices Control) Order, 2013 (DPCO, 2013). The disclosures point to two separate products and two distinct periods of alleged non-compliance. The larger demand relates to Symbicort Turbuhaler 160/4.5 (Inhaler), a respiratory product. A second demand relates to Betaloc-50 (Metoprolol 50 mg tablets), used for hypertension. Both notices require the company to deposit the demanded amounts within 30 days of receipt.

The combined regulatory action highlights sustained scrutiny of price compliance for formulations covered by NPPA ceiling price notifications. It also puts focus on how companies implement revised ceiling prices for inventory already in the market, a recurring enforcement theme under DPCO.

Symbicort demand notice: ₹148.66 crore including interest

AstraZeneca Pharma disclosed on July 30, 2026 that it has received a demand notice from NPPA for alleged overcharging linked to Symbicort Turbuhaler 160/4.5 (Inhaler). The company received this demand notice on July 29, 2026. The notice seeks ₹148.66 crore, inclusive of interest, which the disclosure described as a significant potential financial liability.

According to the disclosure, NPPA alleges that the company overcharged customers for Symbicort during the period from May 2016 to November 2025. The amount demanded includes the principal component plus interest calculated up to August 20, 2026. NPPA has stipulated that payment must be made within 30 days from receipt of the notice.

The Symbicort demand follows a show cause notice issued in September 2025, indicating that the Symbicort matter has been under regulatory examination for months before the demand crystallised into a specific recovery direction.

The show cause stage in 2025: ₹60.49 crore plus interest

In an earlier disclosure dated September 12, 2025, AstraZeneca Pharma India stated it received a show cause notice from NPPA on September 11, 2025. The show cause notice alleged overcharging for batches of “Symbicort Turbuhaler” Inhalation Powder, 60 doses each. NPPA alleged the company marketed or manufactured these batches at prices above the notified ceiling price after relevant price notifications.

The alleged period cited in that 2025 notice was April 2016 to July 2025. The quantum mentioned at the show cause stage was ₹60.49 crore plus interest (INR 604,979,385 plus interest), and the company stated it disputed the quantum. AstraZeneca also said the overall financial implication could not be determined at that stage and clarified that no litigation had been filed in any court or tribunal because the matter was at the show cause stage.

Betaloc-50 demand notice: ₹79,97,457 including interest

Separately, AstraZeneca Pharma India disclosed that it received another NPPA demand notice for ₹79,97,457, inclusive of interest calculated up to August 10, 2026. In crore terms, the demand is about ₹0.80 crore (₹79.97 lakh). The company received this direction on July 27, 2026 and filed the compliance with the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE) on July 28, 2026.

NPPA has alleged that AstraZeneca sold or marketed Betaloc-50 (Metoprolol 50 mg tablets) at a maximum retail price (MRP) higher than the ceiling price notified under DPCO, 2013. It also alleged the company did not implement revised ceiling prices on stocks available in the market following two notifications: S.O. 644(E) dated March 2, 2016 and S.O. 1352(E) dated June 2, 2016. The alleged overcharging period for Betaloc-50 was June to July 2016.

As with the Symbicort demand, NPPA directed deposit of the amount within 30 days from the date of receipt.

What AstraZeneca told the exchanges

In its regulatory filing on the Betaloc-50 matter, AstraZeneca said it is reviewing the demand notice and will take appropriate steps in accordance with applicable law. The company repeated this position in its exchange filing, indicating that its next steps would be driven by its assessment of the demand and the legal options available.

The disclosures do not state that any payment has been made or that a settlement has been reached. They also do not detail whether the company will challenge the notices, beyond stating that it is reviewing and may take legal steps.

Why DPCO pricing disputes often hinge on implementation

NPPA enforcement actions under DPCO typically turn on whether companies price products at or below the notified ceiling price and whether they implement revisions promptly. The Betaloc-50 notice explicitly references alleged non-implementation of revised ceiling prices on “stocks available in the market” after specific notifications in March and June 2016. This highlights an operational compliance issue that is different from, but related to, how pricing is set for fresh supplies.

The Symbicort matter shows how pricing scrutiny can span multiple years. The alleged overcharging windows referenced across the show cause and demand stages span 2016 through 2025, and the demand includes interest calculated into August 2026.

Market impact: liability visibility, timelines, and compliance risk

The immediate market-relevant takeaway is the size and timing of the potential liabilities and the required deposit deadlines. The Symbicort demand notice seeks ₹148.66 crore inclusive of interest, while the Betaloc-50 notice seeks about ₹0.80 crore inclusive of interest. Both require deposit within 30 days from receipt, which creates a clear compliance timeline.

Beyond the absolute amount, these notices signal regulatory persistence in following up on older periods, with interest calculated up to specified dates (August 20, 2026 for Symbicort and August 10, 2026 for Betaloc-50). For investors tracking regulatory risk, the details that matter are the alleged violation periods, the linkage to specific ceiling price notifications, and how the company responds through review and possible legal action.

Key facts at a glance

What to watch next

The next disclosed step to track is whether AstraZeneca deposits the demanded sums, seeks revision, or challenges the directions through legal or administrative remedies. The company has said it is reviewing the Betaloc-50 demand and will take appropriate steps under applicable law, which suggests a decision process is underway.

For Symbicort, the regulatory trail includes the September 2025 show cause notice and the July 2026 demand notice, with the demand now quantified at ₹148.66 crore inclusive of interest. Any further stock exchange filings will likely clarify the company’s approach to the demand and timelines for response or payment.

Conclusion

AstraZeneca Pharma India’s disclosures indicate two NPPA recovery demands under DPCO, 2013: ₹148.66 crore for Symbicort and about ₹0.80 crore for Betaloc-50, both with 30-day deposit requirements. The company has said it is reviewing at least one demand and may take legal steps under applicable law, making future exchange updates the key marker for next developments.